| Journal of Translational Medicine | |
| Melanoma and immunotherapy bridge 2015 | |
| Meeting Abstracts | |
| Maria T. Fierro1 Elena Marra1 Paola Savoia1 Pietro Quaglino1 Francesca Platini2 Florian Stratica2 David Rondonotti2 Oscar Alabiso2 Andrea P. Sponghini2 Lisa Chen3 Jeffrey Chou3 Catherine Harwood4 Isabella Sperduti5 Miklos Kasler6 Christine Horak7 Helene Hardy7 Mary Ruisi8 Joel Jiang8 Camila Flores9 David P. Enot1,10 Benjamin Brady1,11 Magdalena Thurin1,12 Byoung S. Kwon1,13 David F. Stroncek1,14 Federica Sallusto1,15 Klara Eles1,16 Szabolcs Horvath1,16 Stéphane Dalle1,17 Olivier Michielin1,18 Catriona McNeil1,19 Jean-François Baurain2,20 Alfonso Berrocal2,21 Ryan Sullivan2,22 F. Stephen Hodi2,22 Stephen Hodi2,22 Gianluca Di Monta2,23 Mozzillo Nicola2,23 Caracò Corrado2,23 Massimiliano Di Marzo2,23 Marone Ugo2,23 Maria Luisa Di Cecilia2,23 Huibin Yue2,24 Lev Demidov2,25 Adina Stanciu2,26 Sabin Cinca2,26 Madalina Bolovan2,26 Daniil Stoyakovskiy2,27 Luis de la Cruz-Merino2,28 Brigitte Dréno2,29 Caroline Dutriaux3,30 Luc Thomas3,31 Haiying Xu3,32 Axel Hauschild3,33 Reinhard Dummer3,34 Tseng-hui Timothy Chen3,35 Benjamin Weide3,36 Mark Maurer3,37 Alan J. Korman3,37 Hong Wang3,38 David C. Smith3,39 Eugenia Panaitescu4,40 James Larkin4,41 Karen Briscoe4,42 Christophe Borg4,43 Elisabetta Gambale4,44 Michele De Tursi4,44 Alessandra Di Paolo4,44 Consiglia Carella4,44 Joe-Marc Chauvin4,45 Ornella Pagliano4,45 Cindy Sanders4,45 Zhaojun Sun4,45 Julien Fourcade4,45 Hassane M. Zarour4,46 John M. Kirkwood4,47 Antoni Ribas4,48 Keith T. Flaherty4,49 David Hogg5,50 Jason J. Luke5,51 Vashisht G. Y. Nanda5,52 Michael A. Davies5,52 Weiyi Peng5,52 Patrick Hwu5,53 Angela Santoni5,54 Helena Stabile5,54 Angela Gismondi5,54 Carlo M. Croce5,55 Carlo Baldi5,56 Rosario Guarrasi5,56 Pio Zeppa5,56 Stefano Pepe5,56 Antonio Marra5,56 Giovanni Di Giulio5,56 Rosa Russo5,56 Vincenzo Faiola5,56 Celeste Fusciello5,56 Speiser Daniel5,57 Henrik Schmidt5,58 Drew M. Pardoll5,59 Maria Libera Ascierto5,59 Leslie Cope6,60 Ludmila Danilova6,60 Charles G. Drake6,61 Johan Hansson6,62 Maria Wolodarski6,62 Yago Pico de Coaña6,62 Giuseppe V. Masucci6,62 Yuya Yoshimoto6,62 Rolf Kiessling6,62 Isabel Poschke6,63 Giusy Gentilcore6,64 Ani S. Balmanoukian6,65 Erik Wennerberg6,66 Claire Vanpouille-Box6,66 Sandra Demaria6,67 Karsten A. Pilones6,67 George J. Netto6,68 Robert A. Anders6,68 Janis M. Taube6,69 Stefani Spranger7,70 Thomas F. Gajewski7,71 Haidong Tang7,72 Yang-Xin Fu7,72 Yang Wang7,72 Claudio Jommi7,73 Giuseppe Cirino7,74 Giuseppe Ercolano7,74 Chiara Armogida7,74 Elisabetta Panza7,74 Angela Ianaro7,74 Paola De Cicco7,74 Giuseppe Cirin7,74 Silvia C. Formenti7,75 Silvia Formenti7,75 Maria Godeny7,76 Paola Nisticò7,77 Belinda Palermo7,77 MariaLaura Foddai7,77 Cosmo Di Donna7,77 Yangyang Wang7,78 Soldano Ferrone7,78 Theresa S. Pritchard7,79 Tracee L. McMiller7,79 Suzanne L. Topalian7,79 Silviu Voinea8,80 Ornella Franzese8,81 Claus Garbe8,82 Ivor Caro8,83 Caroline Robert8,84 Vincenzo C. Battarra8,85 Rickard Linnskog8,86 Farnaz Moradi8,86 Pontus Berglund8,86 Chandra Prakash Prasad8,86 Tommy Andersson8,86 Rita Mancini8,87 Karin Leandersson8,88 Debora Malpicci8,89 Stefania Guida9,90 Tiziana Cocco9,90 Imma Maida9,90 Maria Capuano9,91 Claudia Marino9,92 Paola Michelozzi9,92 Maurizio Nudo9,92 Riccardo Bono9,92 Gabriella Liszkay9,93 Victoria Atkinson9,94 Jeffrey S. Wasser9,95 Jeffrey A. Sosman9,96 John B. Haanen9,97 Michele Maio9,98 Mario Mandalà9,99 Holbrook Kohrt1,10,100 Craig L Slingluff1,10,101 Alessandro Testori1,10,102 Todd M. Bauer1,10,103 Tim Crook1,10,104 Hexiao Wang1,10,104 Charlotte Proby1,10,104 Alastair Thompson1,10,104 François Aubin1,10,105 Simona Mastroeni1,10,106 Cristina Fortes1,10,106 Ana Carrizossa Anderson1,10,107 Nelofer Syed1,10,108 Francesco Sabbatino1,10,109 Manish Patel1,11,110 Veronica Huber1,11,111 Licia Rivoltini1,11,111 Anthony J. Olszanski1,11,112 Frédéric F. Lehmann1,11,113 Nicole Richie1,11,114 Jeffrey Wallin1,11,114 Marcus Ballinger1,11,114 Edward Cha1,11,114 Xian He1,11,114 Michael B. Atkins1,11,115 Nadège Vimond1,11,116 Alexander Eggermont1,11,117 Andréa Cavalcanti1,11,118 David Enot1,11,119 Guido Kroemer1,12,120 Tara C. Gangadhar1,12,121 Eugenio Fernandez1,12,122 Josep Malvehy1,12,123 Jean-Jacques Grob1,12,124 Laurent Mortier1,12,125 Celeste Lebbé1,12,126 Michaela Semeraro1,12,127 Michaë la Semeraro1,12,128 María Paula Roberti1,12,129 Maha Ayyoub1,13,130 Jonathan M. Pitt1,13,131 Maria-Paula Roberti1,13,131 Vichnou Poirier-Colame1,13,131 Takahiro Yamazaki1,13,131 Marie Vetizou1,13,131 Caroline Flament1,13,132 Aurélien Marabelle1,13,133 Romain Daillere1,13,134 Sylvie Rusakiewicz1,13,135 Laurence Zitvogel1,13,136 Nicolas Jacquelot1,13,137 Anne Caignard1,13,138 Concetta Ragone1,13,139 Vincenzo Ingangi1,13,139 Michele Minopoli1,13,139 Katia Bifulco1,13,139 Roberta Miceli1,14,140 Domenico Mallardo1,14,140 Gabriele Madonna1,14,140 Mariaelena Capone1,14,140 Maria Vincenza Carrier1,14,141 Rosaria Falcon1,14,142 Maria Letizia Motti1,14,143 Paola Queirolo1,14,144 Naoko Imai1,14,145 Hearn J. Cho1,14,145 Sacha Gnjatic1,14,145 Sarah Nataraj1,14,145 Adeeb Rahman1,14,145 Yufan Zhao1,14,146 Lance Leopold1,14,146 Janet Maleski1,14,146 Paul Lorigan1,14,147 Eduardo J. Patriarca1,14,148 Anna Lisa De Presbiteris1,14,148 Fabiola Gilda Cordaro1,14,148 Emilia Caputo1,14,149 Tilman Rau1,15,150 Alessandro Lugli1,15,150 Matias Chacon1,15,151 Nicola Mozzillo1,15,152 Rosa Camerlingo1,15,153 Giuseppe Pirozzi1,15,153 Federica Fratangelo1,15,154 Susan Costantini1,15,155 Luigi Fattore1,15,155 Francesca Capone1,15,155 Gennaro Ciliberto1,15,156 Paolo Antonio Ascierto1,15,157 Rosamaria Pinto1,15,158 Vito Michele Garrisi1,15,158 Simona De Summa1,15,158 Sabino Strippoli1,15,159 Amalia Azzariti1,15,159 Michele Guida1,15,159 Stefania Tommasi1,15,159 Anna Ferretta1,16,160 Cristiana Lo Nigro1,16,161 Laura Lattanzio1,16,161 Franck Pagès1,16,162 Jedd D. Wolchok1,16,163 Achim A. Jungbluth1,16,164 Phillip Wong1,16,164 Jianda Yuan1,16,164 Nikoletta Lendvai1,16,164 Linda Pan1,16,165 Andrew Park1,16,165 Ralph Venhaus1,16,165 Vera Hirsh1,16,166 Silvestris Franco1,16,167 Mannavola Francesco1,16,167 Tucci Marco1,16,167 Passarelli Anna1,16,167 Stucci Stefania1,16,167 Davide Quaresmini1,16,168 Claudia Felici1,16,168 Antonio Doronzo1,16,168 Francesco Mannavola1,16,168 Franco Silvestris1,16,168 Anna Passarelli1,16,168 Stella D’Oronzo1,16,168 Marco Tucci1,16,168 Anna Maria Di Giacomo1,16,169 Michaele Maio1,17,170 Marcella Occelli1,17,171 Carolina Cauchi1,17,171 Marco Merlano1,17,171 Omid Hamid1,17,172 Georgina V. Long1,17,173 Paul B. Chapman1,17,174 Ahmad Tarhini1,17,175 Capone Mariaelena1,17,176 Ascierto Paolo Antonio1,17,176 Madonna Gabriele1,17,176 Margaret K. Callahan1,17,177 Alexander Lesokhin1,17,177 RuthAnn Gordan1,17,177 Neil H. Segal1,17,177 Naiyer A. Rizvi1,17,177 Blessing Agunwamba1,17,177 Stephanie A. Kronenberg1,17,177 Jedd Wolchok1,17,178 Michael A. Postow1,17,179 Valeria De Biasio1,18,180 Christine Gause1,18,181 David R. Kaufman1,18,182 Jeffrey S. Weber1,18,183 Crescenzo D’alterio1,18,184 Stefania Scala1,18,184 Angela Sandru1,18,185 Jonathan Cebon1,18,186 Timea Balatoni1,18,187 Jorge Camarero1,18,188 Matthew Wongchenko1,18,189 Yibing Yan1,18,189 Alba Zappalà1,19,190 Francesca Passarelli1,19,190 Akos Savolt1,19,191 Andras Szollar1,19,191 Emil Farkas1,19,191 Karmele Mujika Eizmendi1,19,192 Orsolya Csuka1,19,193 Judit Olasz1,19,193 Valeria Sorrentino1,19,194 Fara De Murtas1,19,194 Laura Marra1,19,195 Gabriella Aquino1,19,196 Annamaria Anniciello1,19,196 Gerardo Bott1,19,197 Giuseppina Liguori1,19,197 Federica Zito Marino1,19,197 Margherita Cerrone1,19,198 Anna Maria Anniciello1,19,198 Monica Cantile1,19,199 Giosuè Scognamiglio2,20,200 Gerardo Botti2,20,201 Antonello Pessi2,20,202 Alessio Caggiati2,20,203 Shelley Coleman2,20,204 Isabelle Rooney2,20,205 Daniel O. Koralek2,20,205 Ilsung Chang2,20,205 Gil Bar-Sela2,20,206 Arantxa Sancho2,20,207 Sarah Jégou2,20,208 Ivan Marquez-Rodas2,20,209 Viktor Umansky2,21,210 Carolin Blattner2,21,210 Grant A. McArthur2,21,211 Piotr Rutkowski2,21,212 Parneet Cheema2,21,213 Luigi Aurisicchio2,21,214 Peter Boasberg2,21,215 Alan E. Berger2,21,216 Jinshui Fan2,21,216 Chris Cheadle2,21,216 Rodabe Amaria2,21,217 Ari VanderWalde2,21,218 Paolo A. Ascierto2,22,220 Chiara Botti2,22,221 Jessica C. Hassel2,22,222 Carmen Loquai2,22,223 Lars Ny2,22,224 Adam D. Cohen2,22,225 Robert H. I. Andtbacka2,22,226 Gabriella Guida2,22,227 Igor Puzanov2,22,228 Ewa Kalinka-Warzocha2,22,229 Matthew M. Burke2,23,230 Angel Rivera2,23,230 Mario Sznol2,23,230 Amanda Ralabate2,23,230 Harriet Kluger2,23,230 Miri Blank2,23,231 Yehuda Shoenfeld2,23,231 | |
| [1] A.O.U. Città della Salute e della Scienza, S.C. di Dermatologia, Torino, Italy;A.O.U. Maggiore della Carità, S.C. di Oncologia, Novara, Italy;Amgen Inc., Thousand Oaks, CA, USA;Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK;Biostatistics and Scientific Direction, Regina Elena National Cancer Institute, Rome, Italy;Board of Directors, National Institute of Oncology, Budapest, Hungary;Bristol-Myers Squibb, Hopewell, NJ, USA;Bristol-Myers Squibb, Princeton, NJ, USA;CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Institute, Villejuif, France;Cabrini Health, Melbourne, VIC, Australia;Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, USA;Cancer Immunology Branch, Division of Cancer Biology, National Cancer Center, Ilsan, Goyang, Gyeonggi, Korea;Section of Clinical Immunology, Allergy, and Rheumatology, Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA;Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA;Cellular Immunology Laboratory, Institute for Research in Biomedicine, Università della Svizzera Italiana (USI), Via Vincenzo Vela 6, 6500, Bellinzona, Switzerland;Center of Surgical and Molecular Tumorpathology, National Institute of Oncology, Budapest, Hungary;Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, University Claude Bernard Lyon 1, Lyon, France;Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, University Claude Bernard Lyon 1, Lyon, France;Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;Chris O’Brien Lifehouse, Royal Prince Alfred Hospital and Melanoma Institute Australia, Camperdown, NSW, Australia;Chris O’Brien Lifehouse, The Melanoma Institute Australia and Royal Prince Alfred Hospital, Camperdown, Australia;Cliniques Universitaires Saint-Luc, Bruxelles, Belgium;Consorcio Hospital General Universitario de Valencia, Valencia, Spain;Dana-Farber Cancer Institute, Boston, MD, USA;Department Melanoma, Division Surgery of Melanoma, National Cancer Institute “Fondazione Pascale”, Naples, Italy;Department of Biostatistics, Genentech Inc., San Francisco, CA, USA;Department of Biotherapy, N. N. Blokhin Russian Cancer Research Center, Moscow, Russia;Department of Carcinogenesis and Molecular Biology, “Alexandru Trestioreanu” Oncologic Institute, Bucharest, Romania;Department of Chemotherapy, Moscow City Oncology Hospital 62, Krasnogorsk, Russia;Department of Clinical Oncology, Hospital Universitario Virgen Macarena, Seville, Spain;Department of Dermato Cancerology, Nantes University, Nantes, France;Department of Dermato-Oncology, Hôpital Saint André, Bordeaux, France;Hôpital Saint André Centre Hospitalier Universitaire, Bordeaux, France;Department of Dermatology, Centre Hospitalier Lyon Sud, Pierre-Bénite, France;Department of Dermatology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA;Department of Dermatology, University of Kiel, Kiel, Germany;Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland;Dermatologische Klinik, University of Zurich, Zurich, Switzerland;University Hospital of Zurich, Zurich, Switzerland;Universitaets Spital, Zurich, Switzerland;Department of Immunobiology, Yale School of Medicine, 10 Amistad Street, 06519, New Haven, CT, USA;Department of Immunology, Eberhard Karls Universität Tübingen, Tübingen, Germany;Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany;Division of Dermatooncology, Department of Dermatology, University Medical Center, Tübingen, Germany;Department of Immunology, University of Pittsburgh, School of Medicine, 15213, Pittsburgh, PA, USA;Biologics Discovery California, Bristol-Myers Squibb, 94063, Redwood City, CA, USA;Department of Immunology, University of Pittsburgh, School of Medicine, 15213, Pittsburgh, PA, USA;Department of Biostatistics, School of Medicine, University of Pittsburgh, 15213, Pittsburgh, PA, USA;Department of Internal Medicine and Department of Urology, University of Michigan, Ann Arbor, MI, USA;Department of Medical Informatics and Biostatistics, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania;Department of Medical Oncology and Hematology, The Royal Marsden Hospital, London, UK;Department of Medical Oncology, Coffs Harbour Health Campus, Coffs Harbour, NSW, Australia;Department of Medical Oncology, University Hospital of Besancon, 3 Boulevard Alexander Fleming, 25030, Besancon, France;Clinical Investigational Centre, CIC-1431, University Hospital of Besançon, Besançon, France;INSERM U1098, University of Franche-Comté, Besançon, France;Department of Medical, Oral and Biotechnological Sciences, University G. D’Annunzio of Chieti-Pescara, Chieti, Italy;Department of Medicine and Division of Hematology/Oncology, University of Pittsburgh, School of Medicine, 15213, Pittsburgh, PA, USA;Department of Immunology, University of Pittsburgh, School of Medicine, 15213, Pittsburgh, PA, USA;Department of Medicine and Division of Hematology/Oncology, University of Pittsburgh, School of Medicine, 15213, Pittsburgh, PA, USA;Department of Immunology, University of Pittsburgh, School of Medicine, 15213, Pittsburgh, PA, USA;Department of Biostatistics, School of Medicine, University of Pittsburgh, 15213, Pittsburgh, PA, USA;Biologics Discovery California, Bristol-Myers Squibb, 94063, Redwood City, CA, USA;Department of Medicine and Division of Hematology/Oncology, University of Pittsburgh, School of Medicine, 15213, Pittsburgh, PA, USA;Department of Immunology, University of Pittsburgh, School of Medicine, 15213, Pittsburgh, PA, USA;University of Pittsburgh Medical Center, Pittsburgh, PA, USA;University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA;Department of Medicine, Jonsson Comprehensive Cancer Center at University of California Los Angeles, Los Angeles, CA, USA;University of California at Los Angeles Medical Center, Los Angeles, CA, USA;Department of Medicine, Massachusetts General Hospital, Boston, MA, USA;Department of Medicine, Princess Margaret Hospital and University Health Network, Toronto, Canada;Department of Medicine-Section of Hematology/Oncology, University of Chicago, Chicago, USA;Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA;Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA;The University of Texas MD Anderson Cancer Center, Houston, TX, USA;Department of Molecular Medicine, University of Rome “La Sapienza”, Rome, Italy;Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA;Department of Onco-Hematology, AOU S. Giovanni di Dio e Ruggi D’Aragona, University of Salerno, Salerno, Italy;Department of Oncology and Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland;Campbell Family Institute, Princess Margaret Hospital, Toronto, Canada;Department of Oncology, Aarhus University Hospital, Aarhus, Denmark;Department of Oncology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA;Department of Oncology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA;Oncology Bioinformatics Core, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA;Department of Oncology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA;The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA;Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden;Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden;Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany;Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden;Division of Translational Medicine, Sidra Medical and Research Center, Doha, Qatar;Department of Pathology and Department of Medicine-Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA;Department of Pathology, NYU School of Medicine, New York, NY, USA;Department of Pathology, NYU School of Medicine, New York, NY, USA;Department of Radiation Oncology, NYU School of Medicine, New York, NY, USA;Department of Pathology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA;Department of Pathology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA;Department of Dermatology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA;Department of Pathology, University of Chicago, Chicago, IL, USA;Department of Pathology, University of Chicago, Chicago, IL, USA;Department of Medicine, University of Chicago, Chicago, IL, USA;Department of Pathology and Department of Medicine-Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA;The University of Chicago Medicine, Chicago, IL, USA;Department of Pathology, University of Texas Southwestern, Dallas, USA;Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Novara, Italy;Cergas (Centre for Research on Health and Social Care Management), Università Bocconi, Milano, Italy;Department of Pharmacy, University of Naples Federico II, Napoli, Italy;Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA;Department of Radiological Diagnostics, National Institute of Oncology, Budapest, Hungary;Department of Research, Advanced Diagnostics and Technological Innovation, Regina Elena National Cancer Institute, Rome, Italy;Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA;Department of Surgery, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA;Department of Surgical Oncology, Alexandru Trestioreanu” Oncologic Institute, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania;Department of Surgical Oncology, “Carol Davila” University of Medicine and Pharmacy, “Alexandru Trestioreanu” Oncologic Institute, Bucharest, Romania;Department of Systems Medicine, University of Tor Vergata, Rome, Italy;Deptartment of Dermatology, University of Tübingen, Tübingen, Germany;Dermatology Product Development, Genentech Inc., San Francisco, CA, USA;Dermatology Unit, Institut Gustave Roussy, Paris, France;Gustave Roussy, Paris-Sud University, Villejuif Paris-Sud, France;Gustave Roussy and Paris-Sud University, Villejuif Paris-Sud, France;CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;Departments of Dermatology, Cancer Institute Gustave Roussy, Villejuif, France;Clinical Oncology, Melanoma Branch, Gustave Roussy Cancer Institute, Villejuif, France;Dermatology and Oncology surgery of skin growths Department, Hospital of Caserta, Caserta, Italy;Dipartimento di Chirurgia “P. Valdoni”, Sapienza Università di Roma, Rome, Italy;Dipartimento di Chirurgia “P. Valdoni”, Sapienza Università di Roma, Rome, Italy;Dipartimento di Medicina Clinica e Molecolare, Sapienza Università di Roma, Rome, Italy;Dipartimento di Medicina Clinica e Molecolare, Sapienza Università di Roma, Rome, Italy;Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Catanzaro “Magna Graecia”, Catanzaro, Italy;Dipartimento di Scienze Mediche di Base, Neuroscienze e Organi di Senso, Universita degli Studi di Bari, Bari, Italy;Division Dermatology Villa Paola, Capranica, Italy;Division Dermatology, IDI-IRCCS, Rome, Italy;Division of Cancer Services National Institute of Oncology, Budapest, Hungary;Oncodermatology, National Institute of Oncology, Budapest, Hungary;Division of Cancer Services, Princess Alexandra Hospital, Woolloongabba, QLD, Australia;Princess Alexandra Hospital, Gallipoli Medical Research Foundation, Woolloongabba, Greenslopes, QLD, Australia;Gallipoli Medical Research Foundation and Princess Alexandra Hospital, Greenslopes, QLD, Australia;Division of Hematology and Medical Oncology, University of Connecticut Health Center, Farmington, CT, USA;Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA;Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;Division of Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Siena, Italy;University Hospital of Siena, Siena, Italy;Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy;Division of Medical Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy;Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA;Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA;Division of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, VA, USA;Divisione chirurgia dermatoncologica, Europeo di Oncologia, Milan, Italy;Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN, USA;Dundee Cancer Center, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, UK;EA3181, SFR4234, Service de Dermatologie, Université de Franche Comté, Centre Hospitalier Universitaire (CHU), Besançon, France;Epidemiology Unit, IDI-IRCCS, Rome, Italy;Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, 02115, Boston, MA, USA;Faculty of Medicine, Imperial College London, London, UK;Faculty of Pharmacy and Medicine, Department of Medicine, University of Salerno, Baronissi, Salerno, Italy;Department of Onco-Hematology, AOU S. Giovanni di Dio e Ruggi D’Aragona, University of Salerno, Salerno, Italy;Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA;Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;Fox Chase Cancer Center, Philadelphia, PA, USA;GSK Vaccines, Rixensart, Belgium;Genentech, Inc., South San Francisco, CA, USA;Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC, USA;Gustave Roussy Cancer Institute, Villejuif, France;CIC Biotherapie IGR Curie, CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;Laboratory of Immunomonitoring in Oncology (L.I.O), UMS 3655 CNRS / US 23 INSERM, Gustave Roussy Cancer Institute, Villejuif, France;Gustave Roussy Cancer Institute, Villejuif, France;CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;Gustave Roussy Cancer Institute, Villejuif, France;CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;Departments of Dermatology, Cancer Institute Gustave Roussy, Villejuif, France;Department of Surgery, Gustave Roussy Cancer Campus, Villejuif, France;Gustave Roussy Cancer Institute, Villejuif, France;Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Institute, Villejuif, France;Gustave Roussy Cancer Institute, Villejuif, France;Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Institute, Villejuif, France;Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;INSERM, U1138, Paris, France;Université Paris Descartes, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie, Paris, France;Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France;CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Institute, Villejuif, France;Department of Immunobiology, Yale School of Medicine, 10 Amistad Street, 06519, New Haven, CT, USA;Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;Université Paris Descartes, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie, Paris, France;Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France;Hematology-Oncology Division, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA;Hopitaux Universitaires de Geneve;, Geneva, Switzerland;Hospital Clinic i Provincial de Barcelona, Barcelona, Spain;Hospital Timone APHM, Aix-Marseille University, Marseille, France;Hôpital Claude Huriez, Lille, France;Hôpital Saint-Louis University Paris Diderot, Paris, France;INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France;CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;Center of Clinical Investigation Hôpital Necker Enfants Malades, Paris, France;INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France;Center of Clinical Investigation Hôpital Necker Enfants Malades, Paris, France;INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France;Gustave Roussy Cancer Campus, Villejuif, France;CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France;Gustave Roussy Cancer Campus, Villejuif, France;CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;University Paris Sud XI, Kremlin Bicêtre, France;INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France;Gustave Roussy Cancer Institute, Villejuif, France;INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France;Gustave Roussy Cancer Institute, Villejuif, France;CIC Biotherapie IGR Curie, CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France;Gustave Roussy Cancer Institute, Villejuif, France;INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France;CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;University Paris Sud XI, Kremlin Bicêtre, France;INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France;University Paris Sud XI, Kremlin Bicêtre, France;Gustave Roussy Cancer Institute, Villejuif, France;INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France;University Paris Sud XI, Kremlin Bicêtre, France;Gustave Roussy Cancer Institute, Villejuif, France;CIC Biotherapie IGR Curie, CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France;CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France;University Paris Sud XI, Kremlin Bicêtre, France;Gustave Roussy Cancer Institute, Villejuif, France;CIC Biotherapie IGR Curie, CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France;Gustave Roussy Cancer Campus, Villejuif, France;CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, France;INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France;University Paris Sud XI, Kremlin Bicêtre, France;Gustave Roussy Cancer Institute, Villejuif, France;INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France;Gustave Roussy Cancer Campus, Villejuif, France;INSERM U1016, CNRS UMR8104 Cochin Institute, Paris, France;IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy;IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy;IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy;IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy;IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy;Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy;IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy;University Parthenope, Naples, Italy;IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy;University ‘Parthenope’, Naples, Italy;IRCCS San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy;Icahn School of Medicine at Mount Sinai, New York city, USA;Incyte Corporation, Drug Development, Wilmington, DE, USA;Institute of Cancer Sciences, University of Manchester, Manchester, UK;Institute of Genetics and Biophysics –I.G.B., A. Buzzati-Traverso– CNR, Naples, Italy;Institute of Genetics and Biophysics –I.G.B., A. Buzzati-Traverso– CNR, Naples, Italy;Institute of Genetics and Biophysics –I.G.B.– CNR, Naples, Italy;Institute of Pathology, University of Bern, Bern, Switzerland;Instituto Alexander Fleming, Buenos Aires, Argentina;Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy;Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy;IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy;Department of Experimental Oncology, Istituto Nazionale Tumori Fondazione “G. Pascale”, Naples, Italy;Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy;IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy;IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy;Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Naples, Italy;Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Naples, Italy;IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy;Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Naples, Italy;Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura Tumori Fondazione “G. Pascale”, Napoli, Italy;Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy;IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy;IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy;Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy;Istituto Tumori “Giovanni Paolo II, Bari, Italy;Istituto Tumori “Giovanni Paolo II, Bari, Italy;Istituto Tumori “Giovanni Paolo II” I.R.R.C.S., Istituto di ricovero e cura a carattere scientifico, Bari, Italy;Istituto Tumori “Giovanni Paolo II” I.R.R.C.S., Istituto di ricovero e cura a carattere scientifico, Bari, Italy;Dipartimento di Scienze Mediche di Base, Neuroscienze e Organi di Senso, Universita degli Studi di Bari, Bari, Italy;Laboratory of Cancer Genetics and Translational Oncology, S. Croce & amp, Carle Teaching Hospital, Cuneo, Italy;Laboratory of Immunology, Hopital Européen Georges Pompidou, Paris, France;INSERM team 15, Cordeliers Research Center, Paris, France;Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, NY, USA;Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research, Weill Cornell Medical College, New York, NY, USA;Ludwig Center for Cancer Immunotherapy, Department of Immunology and Department of Medicine,, Memorial Sloan-Kettering Cancer Center, New York, NY, USA;Ludwig Institute for Cancer Research, New York, NY, USA;McGill University, MUHC Royal Victoria Hospital, Montreal, QC, Canada;Medical Oncology Unit, Department of Biomedical Sciences and Clinical Oncology, University of Bari ‘Aldo Moro’, Bari, Italy;Medical Oncology Unit, University of Bari ‘Aldo Moro’, Bari, Italy;Medical Oncology and Immunotherapy Division, University Hospital of Siena, Viale Bracci, 14, 53100, Siena, Italy;Medical Oncology and Immunotherapy, Department of Oncology,, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy;Medical Oncology, Oncology Department, S. Croce & amp, Carle Teaching Hospital, Cuneo, Italy;Melanoma Center, The Angeles Clinic and Research Institute, Los Angeles, CA, USA;The Angeles Clinic and Research Institute, Los Angeles, CA, USA;Research Department, The Angeles Clinic and Research Institute, Los Angeles, CA, USA;Melanoma Institute Australia, The University of Sydney and The Mater Hospital, Sydney, Australia;Melanoma Institute Australia, Sydney, NSW, Australia;Melanoma Institute Australia, The University of Sydney, and Mater Hospital, Sydney, NSW, Australia;Melanoma and Immunotherapies Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA;Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, INT “G. Pascale”, Napoli, Italy;Memorial Sloan Kettering Cancer Center, New York, USA;Memorial Sloan Kettering Cancer Center, New York, USA;Ludwig Center for Cancer Immunotherapy, Department of Immunology and Department of Medicine,, Memorial Sloan-Kettering Cancer Center, New York, NY, USA;Memorial Sloan Kettering Cancer Center, New York, USA;Weill Cornell Medical College, New York, NY, USA;Mental Health Department, Hospital of Lauria, Rome, Italy;Merck & Co., Inc., Kenilworth, NJ, USA;Merck Research Laboratories, Merck & Co. Inc., Kenilworth, NJ, USA;Merck & Co., Inc., Kenilworth, NJ, USA;Moffitt Cancer Center, Tampa, FL, USA;Molecular Immunology and Immuneregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Napoli, Italy;Molecular Immunology and Toxicology, National Institute of Oncology, Budapest, Hungary;Center of Surgical and Molecular Tumorpathology, National Institute of Oncology, Budapest, Hungary;Department of Surgical Oncology, Alexandru Trestioreanu” Oncologic Institute, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania;Department of Surgical Oncology, “Carol Davila” University of Medicine and Pharmacy, “Alexandru Trestioreanu” Oncologic Institute, Bucharest, Romania;Olivia Newton-John Cancer Center, Heidelberg, Australia;Oncodermatology, National Institute of Oncology, Budapest, Hungary;Oncology Area, Spanish Medicines Agency and Medical Devices (AEMPS), Madrid, Spain;Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA;Oncology Unit, IDI-IRCCS, Rome, Italy;Oncosurgery, National Institute of Oncology, Budapest, Hungary;Onkologikoa, Donosti, Gipuzkoa, Spain;Pathogenetics, National Institute of Oncology, Budapest, Hungary;Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy;Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy;Pathology Unit, Istituto Nazionale Tumori de Fondazione “G. Pascale”, Napoli, Italy;Pathology Unit, Istituto Nazionale Tumori de Fondazione “G. Pascale”, Napoli, Italy;Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione “G. Pascale”, Napoli, Italy;Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione “G. Pascale”, Napoli, Italy;Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy;Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione “G. Pascale”, Napoli, Italy;Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy;Pathology Unit, Istituto Nazionale Tumori de Fondazione “G. Pascale”, Napoli, Italy;Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione “G. Pascale”, Napoli, Italy;Unit of Pathology, Istituto Nazionale per lo Studio e la cura dei tumori “Fondazione G. Pascale” IRCCS, Naples, Italy;Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA;Pathology Unit, Istituto Nazionale Tumori de Fondazione “G. Pascale”, Napoli, Italy;Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione “G. Pascale”, Napoli, Italy;Unit of Pathology, Istituto Nazionale per lo Studio e la cura dei tumori “Fondazione G. Pascale” IRCCS, Naples, Italy;Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy;Pathology Unit, Istituto Nazionale Tumori de Fondazione “G. Pascale”, Napoli, Italy;PeptiPharma, Viale Città D’Europa 679, 00144, Rome, Italy;Plastic Surgery Unit, IDI-IRCCS, Rome, Italy;Product Development Oncology, Genentech Inc., San Francisco, CA, USA;Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA;Rambam Health Care Campus, Haifa, Israel;Research Institute Hospital Puerta de Hierro Majadahonda, Madrid, Spain;Saint Antoine Hospital, INSERM ERL 1157-CNRS UMR 7203, Paris, France;Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain;Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany;Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim Ruprecht-Karl University of Heidelberg, Mannheim, Germany;Skin and Melanoma Service, Peter MacCallum Cancer Centre, East Melbourne, Australia;Skin and Melanoma Service, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland;Sunnybrook Health Sciences Centre, Toronto, Canada;Takis s.r.l., Rome, Italy;The Angeles Clinic and Research Institute, Los Angeles, CA, USA;The Lowe Family Genomics Core, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA;The University of Texas MD Anderson Cancer Center, Houston, TX, USA;The West Clinic, Memphis, TN, USA;Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy;Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy;Melanoma Institute Australia, Sydney, NSW, Australia;Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy;Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy;University Hospital Heidelberg, Heidelberg, Germany;University Hospital Mainz, 55122, Mainz, Germany;University of Gothenburg, Gothenburg, Sweden;University of Pennsylvania, Philadelphia, PA, USA;University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA;Università di Bari, Bari, Italy;Dipartimento di Scienze Mediche di Base, Neuroscienze e Organi di Senso, Universita degli Studi di Bari, Bari, Italy;Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA;Vanderbilt University Medical Center, Nashville, TN, USA;Wojewódzki Szpital Specjalistyczny im. M., Lodz, Poland;Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT, USA;Zabludowitz Center for Autoimmune Diseases, Sheba Medical Center affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel; | |
| 关键词: Melanoma; Overall Survival; Melanoma Cell; Melanoma Patient; Melanoma Cell Line; | |
| DOI : 10.1186/s12967-016-0791-2 | |
| 来源: Springer | |
 PDF
|
|
【 摘 要 】
contentsMELANOMA BRIDGE 2015KEYNOTE SPEAKER PRESENTATIONSMolecular and immuno-advancesK1 Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanomaVashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A. DaviesK2 Non-mutational adaptive changes in melanoma cells exposed to BRAF and MEK inhibitors help the establishment of drug resistanceGennaro Ciliberto, Luigi Fattore, Debora Malpicci, Luigi Aurisicchio, Paolo Antonio Ascierto, Carlo M. Croce, Rita ManciniK3 Tumor-intrinsic beta-catenin signaling mediates tumor-immune avoidanceStefani Spranger, Thomas F. GajewskiK4 Intracellular tumor antigens as a source of targets of antibody-based immunotherapy of melanomaYangyang Wang, Soldano FerroneCombination therapiesK5 Harnessing radiotherapy to improve responses to immunotherapy in cancerClaire Vanpouille-Box, Erik Wennerberg, Karsten A. Pilones, Silvia C. Formenti, Sandra DemariaK6 Creating a T cell-inflamed tumor microenvironment overcomes resistance to checkpoint blockadeHaidong Tang, Yang Wang, Yang-Xin FuK7 Biomarkers for treatment decisions?Reinhard DummerK8 Combining oncolytic therapies in the era of checkpoint inhibitorsIgor PuzanovK9 Immune checkpoint blockade for melanoma: should we combine or sequence ipilimumab and PD-1 antibody therapy?Michael A. PostowNews in immunotherapyK10 An update on adjuvant and neoadjuvant therapy for melanomAhmad TarhiniK11 Targeting multiple inhibitory receptors in melanomaJoe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sanders, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. ZarourK12 Improving adoptive immune therapy using genetically engineered T cellsDavid F. StroncekTumor microenvironment and biomarkersK13 Myeloid cells and tumor exosomes: a crosstalk for assessing immunosuppression?Veronica Huber, Licia RivoltiniK14 Update on the SITC biomarker taskforce: progress and challengesMagdalena ThurinWorld-wide immunoscore task force: an updateK15 The immunoscore in colorectal cancer highlights the importance of digital scoring systems in surgical pathologyTilman Rau, Alessandro LugliK16 The immunoscore: toward an integrated immunomonitoring from the diagnosis to the follow up of cancer’s patientsFranck PagèsEconomic sustainability of melanoma treatments: regulatory, health technology assessment and market access issuesK17 Nivolumab, the regulatory experience in immunotherapyJorge Camarero, Arantxa SanchoK18 Evidence to optimize access for immunotherapiesClaudio JommiORAL PRESENTATIONSMolecular and immuno-advancesO1 Ipilimumab treatment results in CD4 T cell activation that is concomitant with a reduction in Tregs and MDSCsYago Pico de Coaña, Maria Wolodarski, Yuya Yoshimoto, Giusy Gentilcore, Isabel Poschke, Giuseppe V. Masucci, Johan Hansson, Rolf KiesslingO2 Evaluation of prognostic and therapeutic potential of COX-2 and PD-L1 in primary and metastatic melanomaGiosuè Scognamiglio, Francesco Sabbatino, Federica Zito Marino, Anna Maria Anniciello, Monica Cantile, Margherita Cerrone, Stefania Scala, Crescenzo D’alterio, Angela Ianaro, Giuseppe Cirino, Paolo Antonio Ascierto, Giuseppina Liguori, Gerardo BottiO3 Vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma: final overall survival results of the BRIM-3 studyPaul B. Chapman, Caroline Robert, James Larkin, John B. Haanen, Antoni Ribas, David Hogg, Omid Hamid, Paolo Antonio Ascierto, Alessandro Testori, Paul Lorigan, Reinhard Dummer, Jeffrey A. Sosman, Keith T. Flaherty, Huibin Yue, Shelley Coleman, Ivor Caro, Axel Hauschild, Grant A. McArthurO4 Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanomaMario Sznol, Margaret K. Callahan, Harriet Kluger, Michael A. Postow, RuthAnn Gordan, Neil H. Segal, Naiyer A. Rizvi, Alexander Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda Ralabate, Angel Rivera, Stephanie A. Kronenberg, Blessing Agunwamba, Mary Ruisi, Christine Horak, Joel Jiang, Jedd WolchokCombination therapiesO5 Efficacy and correlative biomarker analysis of the coBRIM study comparing cobimetinib (COBI) + vemurafenib (VEM) vs placebo (PBO) + VEM in advanced BRAF-mutated melanoma patients (pts)Paolo A. Ascierto, Grant A. McArthur, James Larkin, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stoyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Matthew Wongchenko, Ilsung Chang, Daniel O. Koralek, Isabelle Rooney, Yibing Yan, Antoni Ribas, Brigitte DrénoO6 Preliminary clinical safety, tolerability and activity results from a Phase Ib study of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600-mutant metastatic melanomaRyan Sullivan, Omid Hamid, Manish Patel, Stephen Hodi, Rodabe Amaria, Peter Boasberg, Jeffrey Wallin, Xian He, Edward Cha, Nicole Richie, Marcus Ballinger, Patrick HwuO7 Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanomaThomas F. Gajewski, Omid Hamid, David C. Smith, Todd M. Bauer, Jeffrey S. Wasser, Jason J. Luke, Ani S. Balmanoukian, David R. Kaufman, Yufan Zhao, Janet Maleski, Lance Leopold, Tara C. GangadharO8 Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanomaReinhard Dummer, Georgina V. Long, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari VanderWalde, Robert H.I. Andtbacka, Jonathan Cebon, Eugenio Fernandez, Josep Malvehy, Anthony J. Olszanski, Thomas F. Gajewski, John M. Kirkwood, Christine Gause, Lisa Chen, David R. Kaufman, Jeffrey Chou, F. Stephen HodiNews in immunotherapyO9 Two-year survival and safety update in patients (pts) with treatment-naïve advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066Victoria Atkinson, Paolo A. Ascierto, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha, Celeste Lebbé, Lars Ny, Matias Chacon, Paola Queirolo, Carmen Loquai, Parneet Cheema, Alfonso Berrocal, Karmele Mujika Eizmendi, Luis De La Cruz-Merino, Gil Bar-Sela, Christine Horak, Joel Jiang, Helene Hardy, Caroline RobertO10 Efficacy and safety of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL) who were treated beyond progression in CheckMate 066/067Georgina V. Long, Jeffrey S. Weber, James Larkin, Victoria Atkinson, Jean-Jacques Grob, Reinhard Dummer, Caroline Robert, Ivan Marquez-Rodas, Catriona McNeil, Henrik Schmidt, Karen Briscoe, Jean-François Baurain, F. Stephen Hodi, Jedd D. WolchokTumor microenvironment and biomarkersO11 New biomarkers for response/resistance to BRAF inhibitor therapy in metastatic melanomaRosamaria Pinto, Simona De Summa, Vito Michele Garrisi, Sabino Strippoli, Amalia Azzariti, Gabriella Guida, Michele Guida, Stefania TommasiO12 Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma and response to ipilimumabNicolas Jacquelot, David Enot,Caroline Flament,Jonathan M. Pitt, Nadège Vimond, Carolin Blattner, Takahiro Yamazaki, Maria-Paula Roberti, Marie Vetizou, Romain Daillere, Vichnou Poirier-Colame, Michaëla Semeraro, Anne Caignard, Craig L Slingluff Jr, Federica Sallusto, Sylvie Rusakiewicz, Benjamin Weide, Aurélien Marabelle, Holbrook Kohrt, Stéphane Dalle, Andréa Cavalcanti, Guido Kroemer, Anna Maria Di Giacomo, Michaele Maio, Phillip Wong, Jianda Yuan, Jedd Wolchok, Viktor Umansky, Alexander Eggermont, Laurence ZitvogelO13 Serum levels of PD1- and CD28-positive exosomes before Ipilimumab correlate with therapeutic response in metastatic melanoma patientsPassarelli Anna, Tucci Marco, Stucci Stefania, Mannavola Francesco, Capone Mariaelena, Madonna Gabriele, Ascierto Paolo Antonio, Silvestris FrancoO14 Immunological prognostic factors in stage III melanomasMaría Paula Roberti, Nicolas Jacquelot, David P Enot, Sylvie Rusakiewicz, Michaela Semeraro, Sarah Jégou, Camila Flores, Lieping Chen, Byoung S. Kwon, Ana Carrizossa Anderson, Caroline Robert, Christophe Borg, Benjamin Weide, François Aubin, Stéphane Dalle, Michele Maio, Jedd D. Wolchok, Holbrook Kohrt, Maha Ayyoub, Guido Kroemer, Aurélien Marabelle, Andréa Cavalcanti, Alexander Eggermont, Laurence ZitvogelPOSTER PRESENTATIONSMolecular and immuno-advancesP1 Human melanoma cells resistant to B-RAF and MEK inhibition exhibit mesenchymal-like featuresAnna Lisa De Presbiteris, Fabiola Gilda Cordaro, Rosa Camerlingo, Federica Fratangelo, Nicola Mozzillo, Giuseppe Pirozzi, Eduardo J. Patriarca, Paolo A. Ascierto, Emilia CaputoP2 Anti-proliferative and pro-apoptotic effect of ABT888 on melanoma cell lines and its potential role in the treatment of melanoma resistant to B-RAF inhibitorsFederica Fratangelo, Rosa Camerlingo, Emilia Caputo, Maria Letizia Motti, Rosaria Falcone, Roberta Miceli, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Maria Vincenza Carriero, Giuseppe Pirozzi and Paolo Antonio AsciertoP3 Involvement of the L-cysteine/CSE/H2S pathway in human melanoma progressionElisabetta Panza, Paola De Cicco, Chiara Armogida, Giuseppe Ercolano, Rosa Camerlingo, Giuseppe Pirozzi, Giosuè Scognamiglio, Gerardo Botti, Giuseppe Cirino, Angela IanaroP4 Cancer stem cell antigen revealing pattern of antibody variable region genes were defined by immunoglobulin repertoire analysis in patients with malignant melanomaBeatrix Kotlan, Gabriella Liszkay, Miri Blank, Timea Balatoni, Judit Olasz, Emil Farkas, Andras Szollar, Akos Savolt, Maria Godeny, Orsolya Csuka, Szabolcs Horvath, Klara Eles, Yehuda Shoenfeld and Miklos KaslerP5 Upregulation of Neuregulin-1 expression is a hallmark of adaptive response to BRAF/MEK inhibitors in melanomaDebora Malpicci, Luigi Fattore, Susan Costantini, Francesca Capone, Paolo Antonio Ascierto, Rita Mancini, Gennaro CilibertoP6 HuR positively regulates migration of HTB63 melanoma cellsFarnaz Moradi, Pontus Berglund, Karin Leandersson, Rickard Linnskog, Tommy Andersson, Chandra Prakash PrasadP7 Prolyl 4- (C-P4H) hydroxylases have opposing effects in malignant melanoma: implication in prognosis and therapyCristiana Lo Nigro, Laura Lattanzio, Hexiao Wang, Charlotte Proby, Nelofer Syed, Marcella Occelli, Carolina Cauchi, Marco Merlano, Catherine Harwood, Alastair Thompson, Tim CrookP8 Urokinase receptor antagonists: novel agents for the treatment of melanomaMaria Letizia Motti, Katia Bifulco, Vincenzo Ingangi, Michele Minopoli, Concetta Ragone, Federica Fratangelo, Antonello Pessi, Gennaro Ciliberto, Paolo Antonio Ascierto, Maria Vincenza CarrieroP9 Exosomes released by melanoma cell lines enhance chemotaxis of primary tumor cellsFrancesco Mannavola, Stella D’Oronzo, Claudia Felici, Marco Tucci, Antonio Doronzo, Franco SilvestrisP10 New insights in mitochondrial metabolic reprogramming in melanomaAnna Ferretta, Gabriella Guida, Stefania Guida, Imma Maida, Tiziana Cocco, Sabino Strippoli, Stefania Tommasi, Amalia Azzariti, Michele GuidaP11 Lenalidomide restrains the proliferation in melanoma cells through a negative regulation of their cell cycleStella D’Oronzo, Anna Passarelli, Claudia Felici, Marco Tucci, Davide Quaresmini, Franco SilvestrisCombination therapiesP12 Chemoimmunotherapy elicits polyfunctional anti-tumor CD8 + T cells depending on the activation of an AKT pathway sustained by ICOSOrnella Franzese, Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, MariaLaura Foddai, Helena Stabile, Angela Gismondi, Angela Santoni, Paola NisticòP13 Favourable toxicity profile of combined BRAF and MEK inhibitors in metastatic melanoma patientsAndrea P. Sponghini, Francesca Platini, Elena Marra, David Rondonotti, Oscar Alabiso, Maria T. Fierro, Paola Savoia, Florian Stratica, Pietro QuaglinoP14 Electrothermal bipolar vessel sealing system dissection reduces seroma output or time to drain removal following axillary and ilio-inguinal node dissection in melanoma patients: a pilot studyDi Monta Gianluca, Caracò Corrado, Di Marzo Massimiliano, Marone Ugo, Di Cecilia Maria Luisa, Mozzillo NicolaNews in immunotherapyP15 Clinical and immunological response to ipilimumab in a metastatic melanoma patient with HIV infectionFrancesco Sabbatino, Celeste Fusciello1, Antonio Marra, Rosario Guarrasi, Carlo Baldi, Rosa Russo, Di Giulio Giovanni, Vincenzo Faiola, Pio Zeppa, Stefano PepeP16 Immunotherapy and hypophysitis: a case reportElisabetta Gambale, Consiglia Carella, Alessandra Di Paolo, Michele De TursiTumor microenvironment and biomarkersP17 New immuno- histochemical markers for the differential diagnosis of atypical melanocytic lesions with uncertain malignant potentialLaura Marra, Giosuè Scognamiglio, Monica Cantile, Margherita Cerrone, Fara De Murtas, Valeria Sorrentino, Anna Maria Anniciello, Gerardo BottiP18 Utility of simultaneous measurement of three serum tumor markers in melanoma patientsAngela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin CincaP19 The significance of various cut-off levels of melanoma inhibitory activity in evaluation of cutaneous melanoma patientsAngela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin CincaP20 The long noncoding RNA HOTAIR is associated to metastatic progression of melanoma and it can be identified in the blood of patients with advanced diseaseChiara Botti, Giosuè Scognamiglio, Laura Marra, Gabriella Aquino, Rosaria Falcone, Annamaria Anniciello, Paolo Antonio Ascierto, Gerardo Botti, Monica CantileOtherP21 The effect of Sentinel Lymph Node Biopsy in melanoma mortality: timing of dissectionCristina Fortes, Simona Mastroeni, Alessio Caggiati, Francesca Passarelli, Alba Zappalà, Maria Capuano, Riccardo Bono, Maurizio Nudo, Claudia Marino, Paola MichelozziP22 Epidemiological survey on related psychopathology in melanomaValeria De Biasio, Vincenzo C. BattarraIMMUNOTHERAPY BRIDGEKEYNOTE SPEAKER PRESENTATIONSImmunotherapy beyond melanomaK19 Predictor of response to radiation and immunotherapySilvia FormentiK20 Response and resistance to PD-1 pathway blockade: clues from the tumor microenvironmentMaria Libera Ascierto, Tracee L. McMiller, Alan E. Berger, Ludmila Danilova, Robert A. Anders, George J. Netto, Haiying Xu, Theresa S. Pritchard, Jinshui Fan, Chris Cheadle, Leslie Cope, Charles G. Drake, Drew M. Pardoll, Janis M. Taube and Suzanne L. TopalianK21 Combination immunotherapy with autologous stem cell transplantation, protein immunization, and PBMC reinfusion in myeloma patientsSacha Gnjatic, Sarah Nataraj, Naoko Imai, Adeeb Rahman, Achim A. Jungbluth, Linda Pan, Ralph Venhaus, Andrew Park, Frédéric F. Lehmann, Nikoletta Lendvai, Adam D. Cohen, and Hearn J. ChoK22 Anti-cancer immunity despite T cell “exhaustion”Speiser DanielImmunotherapy in oncology (I-O): data from clinical trialK23 The Checkpoint Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)Vera Hirsh
【 授权许可】
CC BY
© The Author(s) 2016
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202311105658506ZK.pdf | 965KB |  download |
878987797
028-85220240
